Status:
RECRUITING
QuantaFlo HD Clinical Validation Study
Lead Sponsor:
Semler Scientific
Conditions:
To Assess Cardiovascular Function
Eligibility:
All Genders
22+ years
Brief Summary
The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the fing...
Eligibility Criteria
Inclusion
- Male and female adult (≥ age 22) subjects with a minimum of 1 of the following:
- A history of Cardiovascular Diseasei or PAD
- Recorded history of at least two of the following
- Hypertension
- Diabetes
- Hyperlipidemia
Exclusion
- Unable to safely perform a forced expiration, or unable to obtain a technically adequate FE test result
- Subjects with a pacemaker or ICD with pacemaker function
- Terminal advanced illness
- Recent cardiothoracic surgery (within 12 months)
- Retinal eye disease with anticoagulants
- History of eye surgery, within 90 days
- Uncontrolled hypertension \>180 mmHg systolic pressure or \>100 mmHg diastolic pressure
- Subjects with severe tremors
Key Trial Info
Start Date :
August 21 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT07219693
Start Date
August 21 2025
End Date
June 30 2026
Last Update
October 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pima Heart and Vascular
Tucson, Arizona, United States, 85741